Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of “Moderate Buy” from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $23.00.

Several research firms have issued reports on ZVRA. Weiss Ratings upgraded shares of Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research report on Tuesday, March 10th. Wall Street Zen lowered shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Guggenheim set a $23.00 target price on shares of Zevra Therapeutics and gave the company a “buy” rating in a research note on Tuesday, March 10th. HC Wainwright set a $26.00 target price on Zevra Therapeutics in a research report on Tuesday, December 30th. Finally, BTIG Research started coverage on Zevra Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $23.00 price target on the stock.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, insider Adrian W. Quartel sold 4,533 shares of Zevra Therapeutics stock in a transaction on Friday, January 30th. The shares were sold at an average price of $8.83, for a total transaction of $40,026.39. Following the sale, the insider owned 9,723 shares in the company, valued at $85,854.09. The trade was a 31.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Joshua Schafer sold 10,500 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $9.19, for a total transaction of $96,495.00. Following the completion of the sale, the insider directly owned 62,278 shares in the company, valued at $572,334.82. This trade represents a 14.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 114,158 shares of company stock worth $1,062,878 over the last quarter. 2.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. CWM LLC increased its stake in Zevra Therapeutics by 399.5% in the third quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after acquiring an additional 2,297 shares during the period. Ameritas Investment Partners Inc. raised its position in Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after purchasing an additional 1,280 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in Zevra Therapeutics during the fourth quarter worth about $53,000. Russell Investments Group Ltd. lifted its stake in Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after purchasing an additional 4,475 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares in the last quarter. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Trading Down 2.6%

Shares of ZVRA stock opened at $9.16 on Friday. The firm has a market capitalization of $537.78 million, a P/E ratio of 6.89 and a beta of 0.91. Zevra Therapeutics has a 1 year low of $6.19 and a 1 year high of $13.16. The firm’s fifty day simple moving average is $9.08 and its 200 day simple moving average is $9.13. The company has a current ratio of 5.68, a quick ratio of 5.63 and a debt-to-equity ratio of 0.40.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.